{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:05:53Z","timestamp":1767834353770,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ejca.2011.06.054","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T07:51:46Z","timestamp":1312271506000},"page":"324-332","source":"Crossref","is-referenced-by-count":70,"title":["An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy"],"prefix":"10.1016","volume":"48","clinical-trial-number":[{"clinical-trial-number":"2007-005460-28","registry":"10.18810\/euctr"},{"clinical-trial-number":"nct00655252","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevil E.","family":"Bavbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petri","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oezlem","family":"Anak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Rosamilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Booth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Pirotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Bodrogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9637","key":"10.1016\/j.ejca.2011.06.054_b0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ejca.2011.06.054_b0010","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2011.06.054_b0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2011.06.054_b0020","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.054_b0025","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u2122). Kidney Cancer. Version 1.2011. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf [accessed February 18, 2011]."},{"issue":"3","key":"10.1016\/j.ejca.2011.06.054_b0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","article-title":"EAU guidelines on renal cell carcinoma: the 2010 update","volume":"58","author":"Ljungberg","year":"2010","journal-title":"Eur Urol"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2011.06.054_b0035","doi-asserted-by":"crossref","first-page":"v137","DOI":"10.1093\/annonc\/mdq206","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Escudier","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2011.06.054_b0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2008.12.010","article-title":"EORTC-GU group expert opinion on metastatic renal cell cancer","volume":"45","author":"de Reijke","year":"2009","journal-title":"Eur J Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2011.06.054_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10555-010-9231-6","article-title":"Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma","volume":"29","author":"Calvo","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ejca.2011.06.054_b0050","doi-asserted-by":"crossref","unstructured":"Patard J-J, Baumert H, Corr\u00e9as J-M, et al. Oncology Committee of the French Association of Urology (AFU). [Recommendations onco-urology 2010: kidney cancer]. Prog Urol 2010;20(Suppl. 4):S323\u201343.","DOI":"10.1016\/S1166-7087(10)70048-8"},{"key":"10.1016\/j.ejca.2011.06.054_b0055","unstructured":"Chaves SS. The pre-travel consultation. Travel-related vaccine-preventable diseases: Hepatitis B. In: Online 2010 Yellow Book. Atlanta, GA: Centers for Disease Control and Prevention, Department of Health and Human Services. http:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2010\/chapter-2\/hepatitis-b.aspx#849 [accessed June 15, 2011]."},{"key":"10.1016\/j.ejca.2011.06.054_b0060","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.0. National Institutes of Health, US Department of Health and Human Services; 2009."},{"issue":"2","key":"10.1016\/j.ejca.2011.06.054_b0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMe068263","article-title":"Renal-cell carcinoma\u2014molecular pathways and therapies","volume":"356","author":"Brugarolas","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2011.06.054_b0070","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.2008.19.9836","article-title":"Metastatic renal cell carcinoma: many treatment options, one patient","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2011.06.054_b0075","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.054_b0080","article-title":"A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options","author":"Bellmunt","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2011.06.054_b0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrclinonc.2009.170","article-title":"Sunitinib in RCC \u2013 expanded access equals expanded benefit?","volume":"6","author":"Choueiri","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2011.06.054_b0090","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1200\/JCO.2008.17.7410","article-title":"Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies","volume":"26","author":"Strumberg","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2011.06.054_b0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2011.06.054_b0100","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.24864","article-title":"Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America","volume":"116","author":"Stadler","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2011.06.054_b0105","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2011.06.054_b0110","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2005","article-title":"NCCN Task Force Report: mTOR inhibition in solid tumors","volume":"6","author":"Figlin","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ejca.2011.06.054_b0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2011.06.054_b0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2011.06.054_b0125","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911004928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911004928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T10:06:21Z","timestamp":1638180381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911004928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0959804911004928"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.06.054","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}